Oncolytics Biotech Inc. (ONCY)
-NasdaqCM | Prev Close: | 2.39 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 7.16 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.60 - 4.93 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 332,312 |
|---|
| Market Cap: | 202.57M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Oncolytics Biotech collaborators to present positive clinical trial data at the 15th Annual World Conference on Lung CancerBriefing.com(Tue, Oct 1)
- Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data at the 15th Annual World Conference on Lung CancerPR Newswire(Tue, Oct 1)
- Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data at the 15th Annual World Conference on Lung CancerCNW Group(Tue, Oct 1)
- Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13at TheStreet(Fri, Sep 13)
- Encouraging Data on Oncolytics' ReolysinZacks(Tue, Sep 10)
- Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming ConferencesPR Newswire(Mon, Sep 9)
- Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming ConferencesCNW Group(Mon, Sep 9)
- Oncolytics rises on lung cancer study resultsAP(Mon, Sep 9)
- Oncolytics Pumps Stock With Worsening Lung Cancer Drug Dataat TheStreet(Mon, Sep 9)
- Five Highly Unusual Hot Stocks on the Move for Monday24/7 Wall St.(Mon, Sep 9)
- Oncolytics Lung Cancer Drug Shrinks Tumors in 92% of Patients in Studyat Fox Business(Mon, Sep 9)
- Canada Stocks to Watch: Cameco, Tourmaline, Vermilion and Oncolyticsat The Wall Street Journal(Mon, Sep 9)
- Oncolytics Biotech® Inc. Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung CancerPR Newswire(Mon, Sep 9)
- Media Advisory - Oncolytics Biotech® Inc. to Present at the 2013 Wedbush PacGrow Life Sciences Management Access ConferenceCNW Group(Tue, Aug 13)
- Media Advisory - Oncolytics Biotech® Inc. to Present at the 2013 Wedbush PacGrow Life Sciences Management Access ConferencePR Newswire(Tue, Aug 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.28 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers.
View More
0.41%